Literature DB >> 20656900

Pathology of inhalational anthrax animal models.

N A Twenhafel1.   

Abstract

Anthrax is a lethal disease caused by the bacterium Bacillus anthracis. There are three principal forms of the disease in humans-cutaneous, gastrointestinal, and inhalational-depending on the route of exposure. Of these, inhalational anthrax is the most dangerous; it is rapidly fatal; and it has been used as a deadly biological warfare agent in the last decade. Suitable animal models of inhalational anthrax have been utilized to study pathogenesis of disease, investigate bacterial characteristics such as virulence, and test effectiveness of vaccines and therapeutics. To date, mice, guinea pigs, rabbits, and nonhuman primates are the principal animal species used to study inhalational anthrax. Mice are valuable in studying early pathogenesis and bacterial characteristics. Few pathologic changes occur in the mouse models but may include marked bacteremia and lymphocyte destruction in the spleen and mediastinal lymph nodes. Rabbits and guinea pigs rapidly develop fulminate systemic disease, and pathologic findings often include necrotizing lymphadenitis; splenitis; pneumonia; vasculitis; and hemorrhage, congestion, and edema in multiple tissues. Nonhuman primates consistently develop the full range of classic lesions of human inhalational anthrax, including meningitis; lymphadenitis; splenitis; mediastinitis; pneumonia; vasculitis; and hemorrhage, congestion, and edema in multiple tissues. This review focuses on basic characteristics of the bacterium and its products, key aspects of pathogenesis, and the pathologic changes commonly observed in each animal model species.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20656900     DOI: 10.1177/0300985810378112

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  39 in total

1.  Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax.

Authors:  Bethany Biron; Katie Beck; David Dyer; Marc Mattix; Nancy Twenhafel; Aysegul Nalca
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Monocyte procoagulant responses to anthrax peptidoglycan are reinforced by proinflammatory cytokine signaling.

Authors:  Narcis Ioan Popescu; Alanson Girton; Tarea Burgett; Kessa Lovelady; K Mark Coggeshall
Journal:  Blood Adv       Date:  2019-08-27

Review 3.  The non-human primate model of tuberculosis.

Authors:  D Kaushal; S Mehra; P J Didier; A A Lackner
Journal:  J Med Primatol       Date:  2012-03-20       Impact factor: 0.667

4.  Global metabolomic analysis of a mammalian host infected with Bacillus anthracis.

Authors:  Chinh T Q Nguyen; Vivekananda Shetty; Anthony W Maresso
Journal:  Infect Immun       Date:  2015-10-05       Impact factor: 3.441

5.  The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques.

Authors:  Trudy H Grossman; Michael S Anderson; Lindsay Drabek; Melanie Gooldy; Henry S Heine; Lisa N Henning; Winston Lin; Joseph V Newman; Rene Nevarez; Kaylyn Siefkas-Patterson; Anne K Radcliff; Joyce A Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 6.  Antitoxin Treatment of Inhalation Anthrax: A Systematic Review.

Authors:  Eileen Huang; Satish K Pillai; William A Bower; Katherine A Hendricks; Julie T Guarnizo; Jamechia D Hoyle; Susan E Gorman; Anne E Boyer; Conrad P Quinn; Dana Meaney-Delman
Journal:  Health Secur       Date:  2015 Nov-Dec

7.  Deterministic models of inhalational anthrax in New Zealand white rabbits.

Authors:  Bradford Gutting
Journal:  Biosecur Bioterror       Date:  2014-02-14

8.  Bacillus anthracis has two independent bottlenecks that are dependent on the portal of entry in an intranasal model of inhalational infection.

Authors:  David E Lowe; Stephen M C Ernst; Christine Zito; Jason Ya; Ian J Glomski
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

9.  Pathology and pathophysiology of inhalational anthrax in a guinea pig model.

Authors:  Vladimir Savransky; Daniel C Sanford; Emily Syar; Jamie L Austin; Kevin P Tordoff; Michael S Anderson; Gregory V Stark; Roy E Barnewall; Crystal M Briscoe; Laurence Lemiale-Biérinx; Sukjoon Park; Boris Ionin; Mario H Skiadopoulos
Journal:  Infect Immun       Date:  2013-01-28       Impact factor: 3.441

10.  Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatment.

Authors:  Jason E Comer; Bryan D Ray; Lisa N Henning; Gregory V Stark; Roy E Barnewall; Jason M Mott; Gabriel T Meister
Journal:  Clin Vaccine Immunol       Date:  2012-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.